Gene-gene interactions in a context of individual variability in antipsychotic drug pharmacogenomics

Current Pharmacogenomics and Personalized Medicine

Volumn 9, Issue 4, 2011, Pages 323-331

  Lin, Eugene ^a,b   Tsai, Shih Jen ^c,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b VITA GENOMICS INC   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Antipsychotic drug; Asia pacific; Gene gene interaction; Genome wide association study; Metabolic syndrome; Personalized medicine; Single nucleotide polymorphisms

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 70; INSULIN; INTERLEUKIN 1ALPHA; LEPTIN; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHODIESTERASE VII; RISPERIDONE; SEROTONIN 2C RECEPTOR;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BAYES THEOREM; DRUG EFFICACY; GENE INDUCTION; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PARKINSONISM; PHARMACOGENOMICS; PHENOTYPE; POSITIVE AND NEGATIVE SYNDROME SCALE; QT PROLONGATION; RESTLESS LEGS SYNDROME; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA; TREATMENT RESPONSE;

EID: 83455238079     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569211798377180     Document Type: Article

References (76)

1. Picchioni MM, Murray RM. Schizophrenia. BMJ 2007; 335(7610): 91-95.
2. Buckley PF, Miller BJ, Lehrer DS, et al. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009; 35(2): 383-402.
3. van Os J, Kapur S. Schizophrenia. Lancet 2009; 374(9690): 635-645.
4. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011; 7(1): 9-37.
5. Cacabelos R, Hashimoto R, Takeda M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatry Clin Neurosci 2011; 65(1): 3-19.
6. Bell JT, Wallace C, Dobson R, et al. Two-dimensional genomescan identifies novel epistatic loci for essential hypertension. Hum Mol Genet 2006; 15: 1365-1374.
7. Carlborg O, Haley CS. Epistasis: too often neglected in complex trait studies. Nature 2004; 5: 618-625.
8. Lin E, Hwang Y, Liang KH, et al. Pattern-recognition techniques with haplotype analysis in pharmacogenomics. Pharmacogenomics 2007; 8: 75-83.
9. Lin E, Hwang Y, Chen EY. Gene-gene and gene-environment interactions in interferon therapy for chronic hepatitis C. Pharmacogenomics 2007; 8: 1327-1335.
10. Lin E, Hsu SY. A Bayesian approach to gene-gene and geneenvironment interactions in chronic fatigue syndrome. Pharmacogenomics 2009; 10: 35-42.
11. Musani SK, Shriner D, Liu N, et al. Detection of gene x gene interactions in genome-wide association studies of human population data. Hum Hered 2007; 63(2): 67-84.
12. Motsinger AA, Ritchie MD, Reif DM. Novel methods for detecting epistasis in pharmacogenomics studies. Pharmacogenomics 2007; 8: 1229-1241.
13. Phillips PC. Epistasis--the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet 2008; 9: 855-867.
14. Cordell HJ. Genome-wide association studies: Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 2009; 10: 392-404.
15. Moore JH, Williams SM. Epistasis and its implications for personal genetics. Am J Hum Genet 2009; 85: 309-320.
16. Ma DQ, Whitehead PL, Menold MM, et al. Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. Am J Hum Genet 2005; 77: 377-388.
17. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogenmetabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69: 138-147.
18. Ritchie MD, Motsinger AA. Multifactor dimensionality reduction for detecting gene-gene and gene-environment interactions in pharmacogenomics studies. Pharmacogenomics 2005; 6: 823-834.
19. Lou XY, Chen GB, Yan L, et al. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet 2007; 80: 1125-1137.
20. Jakobsdottir J, Conley YP, Weeks DE, et al. C2 and CFB genes in age-related maculopathy and joint action with CFH and LOC387715 genes. PLoS One 2008; 3: e2199.
21. Chan IH, Tang NL, Leung TF, et al. Study of gene-gene interactions for endophenotypic quantitative traits in Chinese asthmatic children. Allergy 2008; 63: 1031-1039.
22. Lin E, Lin CG, Wang JY, et al. Gene-gene interactions among genetic variants from seven candidate genes with pediatric asthma in a Taiwanese population. Current Topics in Genetics 2008; 3: 83-88.
23. Liu J, Sun K, Bai Y, et al. Association of three-gene interaction among MTHFR, ALOX5AP and NOTCH3 with thrombotic stroke: a multicenter case-control study. Hum Genet 2009; 125: 649-656.
24. Lin E, Pei D, Huang YJ, et al. Gene-gene interactions among genetic variants from obesity candidate genes for nonobese and obese populations in type 2 diabetes. Genet Test Mol Biomarkers 2009; 13: 485-493.
25. Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009; 7: 972-980.
26. Wu LS, Hsieh CH, Pei D, et al. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant 2009; 24: 3360-3366.
27. Lin E, Hong CJ, Hwang JP, et al. Gene-gene interactions of the brain-derived neurotrophic-factor and neurotrophic tyrosine kinase receptor 2 genes in geriatric depression. Rejuvenation Res 2009; 12: 387-393.
28. Neuman RJ, Wasson J, Atzmon G, et al. Gene-gene interactions lead to higher risk for development of type 2 diabetes in an Ashkenazi Jewish population. PLoS One 2010; 5: e9903.
29. Lin E, Chen PS, Chang HH, et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1167-1172.
30. Li MD, Lou XY, Chen G, et al. Gene-gene interactions among CHRNA4, CHRNB2, BDNF, and NTRK2 in nicotine dependence. Biol Psychiatry 2008; 64: 951-957.
31. Pae CU, Drago A, Patkar AA, et al. Epistasis between a set of variations located in the TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotic treatment. Eur Neuropsychopharmacol 2009; 19: 806-811.
32. Du Y, Wan YJ. The interaction of reward genes with environmental factors in contribution to alcoholism in mexican americans. Alcohol Clin Exp Res 2009; 33: 2103-2112.
33. Beretta L, Santaniello A, van Riel PL, et al. Survival dimensionality reduction (SDR): development and clinical application of an innovative approach to detect epistasis in presence of right-censored data. BMC Bioinformatics 2010; 11: 416.
34. Lin E, Hwang Y, Wang SC, et al. An artificial neural network approach to the drug efficacy of interferon treatments. Pharmacogenomics 2006; 7: 1017-1024.
35. Rumelhart DE, Hinton GE, William RJ. Learning internal representation by error propagation. Parallel Distributed Processing: Explorations. In: The Micro-Structure of Cognition, vol.1, Foundations. MIT Press: Cambridge, MA, 1996.
36. Kung SY, Hwang JN. Neural networks for intelligent multimedia processing. Proceedings of the IEEE 1998; 86: 1244-1272.
37. Bishop CM. Neural Networks for Pattern Recognition. Clarendon Press: Oxford, UK, 1995.
38. Hastie T, Tibshirani R, Friedman JH. The Elements of Statistical Learning. Springer-Verlag: New York, USA, 2001.
39. Hirschhorn JN, Daly MI. Genome-wide association studies for common diseases and complex traits. Nature Review Genet 2005; 6: 95-108.
40. North BV, Curtis D, Cassell PG, et al. Assessing optimal neural network architecture for identifying disease-associated multi marker genotypes using a permutation test, and application to calpain 10 polymorphisms associated with diabetes. Ann of Human Genet 2003; 67348-67356.
41. George EI, McCulloch RE. Variable selection via Gibbs sampling. Journal of the American Statistical Association 1993; 88: 881-889.
42. Oh C, Ye KQ, He Q, et al. Locating disease genes using Bayesian variable selection with the Haseman-Elston method. BMC Genet 2003; 4: S69.
43. George EI, McCulloch RE. Approaches for Bayesian variable selection. Statistica Sinica 1997; 7: 339-374.
44. Oh C, Wang S, Liu N, et al. A Bayesian genome screening of maximum number of drinks as an alcoholism phenotype with the new Haseman-Elston method. BMC Genet 2005; 6: S116.
45. Lin E, Huang LC. Identification of significant genes in genomics using Bayesian variable selection methods. Advances and Applications in Bioinformatics and Chemistry 2008; 1: 13-18.
46. Zhang Y, Liu JS. Bayesian inference of epistatic interactions in case-control studies. Nat Genet 2007; 39: 1167-1173.
47. Souza RP, Romano-Silva MA, Lieberman JA, et al. Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. J Psychiatr Res 2010; 44(11): 700-706.
48. Blasi G, Napolitano F, Ursini G, et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci USA 2011; 108(3): 1158-1163.
49. Liou YJ, Bai YM, Lin E, et al. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J. 2010 Sep 28. [Epub ahead of print]
50. Park YM, Lee HJ, Kang SG, et al. Lack of Association between glutathione S-transferase-M1, -T1, and -P1 polymorphisms and olanzapine-induced weight gain in Korean schizophrenic patients. Psychiatry Investig 2010; 7(2): 147-152.
51. Yevtushenko OO, Cooper SJ, O'Neill R, et al. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 2008; 192(6): 424-428.
52. Gregoor JG, Mulder H, Cohen D, et al. Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication. J Clin Psychopharmacol 2010; 30(6): 702-705.
53. Kang SG, Lee HJ, Choi JE, et al. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum Psychopharmacol 2009; 24(1): 55-60.
54. Park SW, Lee JG, Kong BG, et al. Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin Neurosci 2009; 63(4): 433-439.
55. Zai CC, Romano-Silva MA, Hwang R, et al. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophr Res 2008; 106(2- 3): 248-252.
56. Zai CC, Tiwari AK, De Luca V, et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009; 19(5): 317-28.
57. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13(5): 544-556.
58. Kang SG, Lee HJ, Choi JE, et al. Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia. Neuropsychobiology 2008; 57(1-2): 49-54.
59. Kang SG, Park YM, Choi JE, et al. Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia. Hum Psychopharmacol 2010; 25(5): 397-403.
60. Johnson AD, O'Donnell CJ. An open access database of genomewide association results. BMC Med Genet 2009; 10: 6.
61. Christensen K, Murray JC. What genome-wide association studies can do for medicine. N Engl J Med 2007; 356: 1094-1097.
62. Need AC, Goldstein DB. Whole genome association studies in complex diseases: where do we stand? Dialogues Clin Neurosci 2010; 12: 37-46.
63. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008; 299(11): 1335-1344.
64. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011; 16(1): 76-85.
65. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 2011; 36(3): 616-626.
66. Ikeda M, Tomita Y, Mouri A, et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 2010; 67(3): 263-269.
67. Adkins DE, Aberg K, McClay JL, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2011; 16(3): 321-332.
68. Aberg K, Adkins DE, Bukszár J, et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67(3): 279-282.
69. Alkelai A, Greenbaum L, Rigbi A, et al. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 2009; 206(3): 491-499.
70. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009; 14(11): 1024-1031.
71. Lerer B, Segman RH. Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. Dialogues Clin Neurosci 2006; 8(1): 85-94.
72. Hsieh CH, Hung YJ, Pei D, et al. Pilot association study between a common variant in the non-muscle myosin heavy chain 9 (MYH9) gene and diabetic renal disease in a Taiwanese population with type 2 diabetes. The Application of Clinical Genetics 2010; 3: 17-22.
73. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 2010; 11: 415-425.
74. Wheeler DA, Srinivasan M, Egholm M, et al. The complete genome of an individual by massively parallel DNA sequencing. Nature 2008; 452: 872-876.
75. Ng PC, Kirkness EF. Whole genome sequencing. Methods Mol Biol 2010; 628: 215-226.
76. Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet 2009; 85: 142-154.